Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Tempus AI — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.17 (market cap $12.87B), while Tempus AI trades at $70.93 (market cap $12.58B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF and Tempus AI are close in size by market cap, and Tempus AI is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Tempus AI for 23 Days on average.
| EMB | TEM | |
|---|---|---|
Market Cap | $12.87B | $12.58B |
Volume | 14,946,002 | 7,444,569 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $97.74 | $96.39 |
52-Week Low | $90.14 | $41.55 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | — | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB stock trades at $90.96, up 0.2% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company has announced several upcoming dividends in late 2026. Recent news highlights broader market risks from rising bond yields and a focus on income generation from fixed-income assets.
The outlook for EMB is cautious, with technical indicators suggesting near-term pressure. Investment opportunity hinges on its income profile via dividends, but limited fundamental data and bearish sentiment pose risks. Investors should weigh the income potential against market volatility and sparse public financial disclosures.
Tempus AI (TEM) trades at $69.28, down 1.44% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth (2026: $1.4B) but remains unprofitable with negative margins. Recent FDA clearance for ECG-MR AI product and ESMO Congress presentations highlight innovation momentum. Analyst consensus is strongly bullish with 64% buy ratings and $72.60 price target.
TEM offers growth potential in AI-driven healthcare diagnostics but carries significant execution risk due to persistent losses. The stock's high P/S ratio (8.61) reflects growth expectations, yet negative ROE (-67.44%) and insider selling warrant caution. Upside depends on profitability improvements and commercial adoption of new AI products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
